

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  39D0195442	<b>(X3) Date Survey Completed</b>  08/14/2024
<b>Name of Provider or Supplier</b>  Brookside Clinical Lab Inc	<b>Street Address, City, State</b>  2901 W Duttons Mill Road, Suite 100, Aston, PA	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of the CASPER 155 Report and graded results from the proficiency testing (PT) organization, College of American Pathologists (CAP), the laboratory failed to successfully participate in proficiency testing for the toxicology analytes: Carbamazepine (Carb) and Gentamicin (Gent). Refer to D2118.</p>
<b>D2118</b>	<p><b>TOXICOLOGY</b> CFR(s): 493.845(f)</p> <p>Failure to achieve satisfactory performance for the same analyte or test in two</p>

consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of the CASPER 155 Report and graded results from the proficiency testing (PT) organization, College of American Pathologists (CAP), the laboratory failed to achieve an overall testing score of satisfactory performance for the toxicology analytes: Carbamazepine (Carb) and Gentamicin (Gent). The laboratory had unsatisfactory scores for C-C 2023 General Chemistry/Therapeutic Drugs (3rd event of 2023), C-A 2024 General Chemistry/Therapeutic Drugs (1st event of 2024), and C-B 2024 General Chemistry/Therapeutic Drugs (2nd event of 2024). Findings include: Subspecialty Year Event Score Carb 2023 3 60% Carb 2024 2 0% Gent 2024 1 0% Gent 2024 2 0%